Skip navigation
Browsing by Author Goh, J. C.
Showing results 1 to 2 of 2
| Preview | Issue Date | Title / Name | Author(s) |
| Aug-2023 | Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial | Antonarakis, E.; Park, S. H.; Goh, J. C.; Shin, S. J.; Lee, J. L.; Mehra, N.; Dermott, R.; Sala-Gonzalez, N.; Fong, P. C.; Greil, R.; Retz, M.; Sade, J. P.; Yanez, P.; Huang, Y.; Begbie, S. D.; et. al; Begbie, Stephen | |
| Feb-2024 | A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma | Conduit, C.; Davis, I. D.; Goh, J. C.; Kichenadasse, G.; Gurney, H.; Harris, C. A.; Pook, D.; Krieger, L.; Parnis, F.; Underhill, C.; Adams, D.; Roncolato, F.; Joshua, A.; Ferguson, T.; Prithviraj, P.; Morris, M.; Harrison, M.; Begbie, S.; Hovey, E.; George, M.; Liow, E. C.; Link, E. K.; McJannett, M.; Gedye, C.; Australian and New Zealans Urogental and Prostrate Cancer Trils Group (ANZUP); UNISoN Investigators; Begbie, Stephen | |
